Diabetes News Archive

WASHINGTONThe diabetes pill Avandia has been used by millions of patients and racked up billions in sales in more than a decade on the market.

For area diabetes patients, treatment options for the chronic disease are clouded by uncertainty as experts spar over the safety of Glaxo Smith Kline's controversial drug, Avandia.

The diabetes pill Avandia has been used by millions of patients and racked up billions in sales in more than a decade on the market. This week the Food and Drug Administration is trying to answer a se

Popular diabetes drug Avandia is at risk of being pulled from store shelves after being linked to serious, even fatal, side effects.

The diabetes pill Avandia has been used by millions of patients and racked up billions in sales in more than a decade on the market. This week the Food and Drug Administration is trying to answer a seemingly simple question: Does it cause heart attacks? Food and Drug Administration - Diabetes mellitus - Rosiglitazone - Heart - Health

High-stakes meeting on Avandia exposes internal rifts among FDA scientists Food and Drug Administration - GlaxoSmithKline - Health - Conditions and Diseases - Diabetes

The diabetes pill Avandia has been used by millions ofpatients and racked up billions in sales in more than a decade on the market. This week the Food and Drug Administration is trying to answer a seemingly simple question:...

The diabetes pill Avandia has been used by millions of patients and racked up billions in sales in more than a decade on the market. This week the Food and Drug Administration is trying to answer a seemingly simple question: Does it cause heart attacks? It's... Food and Drug Administration - Diabetes mellitus - Heart - GlaxoSmithKline - Rosiglitazone

The diabetes pill Avandia has been used by millions of patients and racked up billions in sales in more than a decade on the market. This week the Food and Drug Administration is trying to answer a seemingly simple question:...

High-stakes meeting on Avandia exposes internal rifts among FDA scientists Diabetes - Rosiglitazone - Health - Conditions and Diseases - Endocrine Disorders

The diabetes pill Avandia has been used by millions of patients and racked up billions in sales in more than a decade on the market. This week the Food and Drug Administration is trying to answer a seemingly simple question: Does it cause heart attacks? Food and Drug Administration - Diabetes mellitus - Rosiglitazone - Heart - GlaxoSmithKline

The diabetes pill Avandia has been used by millions of patients and racked up billions in sales in more than a decade on the market. This week the Food and Drug Administration is trying to answer a seemingly simple question: Does it cause heart attacks?

Expert answers on a condition that affects 23.6 million Americans. Diabetes mellitus - Pancreas - Health - Conditions and Diseases - Endocrine Disorders

A diabetes drug made by a Research Triangle Park pharmaceutical company is the subject of a hearing in Washington. For the next few days, an FDA panel will hold hearings concerning Avandia, a drug created by Glaxo-Smithkline.

Could Avandia be the drug industrys ReGen? The New York Times reported Tuesday that for over a decade, GlaxoSmithKline hid the results of its own study that showed its diabetes drug Avandia provided clear signs that it was riskier to the heart. The Food and Drug Administration ultimately approved Avandia. But in 2007, a doctor at the [...]

Leaders of Black, South Asian and Turkish communities in London have been trained as Diabetes UK Community Champions to help raise awareness of Type 2 diabetes among people from minority ethnic communities at risk of developing the condition. In white people Type 2 diabetes usually occurs over the age of 40, but black and South Asian people can get Type 2 diabetes from the age of around 25 ...

In the fall of 1999, drug giant SmithKline Beecham secretly began a study to find out whether its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda. But the study's results, completed that same year, were disastrous. Not only was Avandia no better than Actos, but the study also provided clear signs that it was riskier to the heart.